Guillain-Barre Syndrome and H1N1: What You Need to Know
A study outlined in the Journal of the American Medical Association links the H1N1 Flu vaccine with a small increased risk of developing Guillain-Barre Syndrome. Reuters Health reported on a research study conducted at Laval University in Quebec City which tracks newly-diagnosed cases of Guillain-Barre in the six months after H1N1 vaccination began in Quebec. Their findings indicated that there is a correlation between the H1N1 flu shot and people over the age of 50 developing Guillain-Barre.
Dr. Claudia Vellozzi, deputy director of the Immunization Safety Office at the U.S. Centers for Disease Control and Prevention said that those findings were similar to other studies in the United States after the 2009 H1N1 vaccination campaign.
Guillain-Barré Syndrome (GBS) is a disorder where a patient’s immune system goes haywire and attacks the peripheral nervous system. The symptoms of Guillain-Barre Syndrome can begin anywhere from one day to several weeks after a vaccination but usually peak around one to two weeks after the shot is given. The chronic version of GBS is known as Chronic Inflammatory Demyelinating Polyneuropathy or CIDP. Researchers continue to monitor any correlation between the vaccine and the development of Guillain-Barre Syndrome.
Guillain-Barre Syndrome related vaccine cases are some of the most common that our Firm sees. Review some of the more recent decisions through the United States Court of Federal Claims awarding compensation to our clients.
Read more information on: how to file a vaccine injury claim.